Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2453091rdf:typepubmed:Citationlld:pubmed
pubmed-article:2453091lifeskim:mentionsumls-concept:C0029925lld:lifeskim
pubmed-article:2453091lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:2453091lifeskim:mentionsumls-concept:C0079083lld:lifeskim
pubmed-article:2453091lifeskim:mentionsumls-concept:C0031928lld:lifeskim
pubmed-article:2453091lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:2453091lifeskim:mentionsumls-concept:C0729066lld:lifeskim
pubmed-article:2453091lifeskim:mentionsumls-concept:C0085752lld:lifeskim
pubmed-article:2453091pubmed:issue2lld:pubmed
pubmed-article:2453091pubmed:dateCreated1988-6-23lld:pubmed
pubmed-article:2453091pubmed:abstractTextEleven untreated patients with advanced ovarian cancer were studied for tolerance and response to combination treatment with fixed doses of adriamycin (45 mg/m2) and cyclophosphamide (600 mg/m2) + escalating doses of carboplatin. At the first dose level of carboplatin (200 mg/m2), toxicity was acceptable. With carboplatin at 300 mg/m2, severe hematologic toxicity was observed. The dose-limiting toxicity was leukopenia. Although carboplatin was administered without any hydration, no patient experienced renal toxicity. Eight objective responses were observed in 9 clinically evaluable patients. At second look surgery, 3 complete responses and 4 partial responses were documented. Polychemotherapy with JAC (carboplatin, 200 mg/m2, adriamycin, 45 mg/m2, and cyclophosphamide, 600 mg/m2) is administrable with acceptable toxicity.lld:pubmed
pubmed-article:2453091pubmed:languageenglld:pubmed
pubmed-article:2453091pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2453091pubmed:citationSubsetIMlld:pubmed
pubmed-article:2453091pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2453091pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2453091pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2453091pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2453091pubmed:statusMEDLINElld:pubmed
pubmed-article:2453091pubmed:monthAprlld:pubmed
pubmed-article:2453091pubmed:issn0300-8916lld:pubmed
pubmed-article:2453091pubmed:authorpubmed-author:RossiLLlld:pubmed
pubmed-article:2453091pubmed:authorpubmed-author:RagniNNlld:pubmed
pubmed-article:2453091pubmed:authorpubmed-author:FogliaGGlld:pubmed
pubmed-article:2453091pubmed:authorpubmed-author:ChiariKKlld:pubmed
pubmed-article:2453091pubmed:authorpubmed-author:BruzzoneMMlld:pubmed
pubmed-article:2453091pubmed:authorpubmed-author:YonemitsuHHlld:pubmed
pubmed-article:2453091pubmed:authorpubmed-author:GuercioEElld:pubmed
pubmed-article:2453091pubmed:authorpubmed-author:BentivoglioGGlld:pubmed
pubmed-article:2453091pubmed:authorpubmed-author:GiacconeGGlld:pubmed
pubmed-article:2453091pubmed:authorpubmed-author:CarninoFFlld:pubmed
pubmed-article:2453091pubmed:issnTypePrintlld:pubmed
pubmed-article:2453091pubmed:day30lld:pubmed
pubmed-article:2453091pubmed:volume74lld:pubmed
pubmed-article:2453091pubmed:ownerNLMlld:pubmed
pubmed-article:2453091pubmed:authorsCompleteNlld:pubmed
pubmed-article:2453091pubmed:pagination217-20lld:pubmed
pubmed-article:2453091pubmed:dateRevised2008-12-12lld:pubmed
pubmed-article:2453091pubmed:meshHeadingpubmed-meshheading:2453091-...lld:pubmed
pubmed-article:2453091pubmed:meshHeadingpubmed-meshheading:2453091-...lld:pubmed
pubmed-article:2453091pubmed:meshHeadingpubmed-meshheading:2453091-...lld:pubmed
pubmed-article:2453091pubmed:meshHeadingpubmed-meshheading:2453091-...lld:pubmed
pubmed-article:2453091pubmed:meshHeadingpubmed-meshheading:2453091-...lld:pubmed
pubmed-article:2453091pubmed:meshHeadingpubmed-meshheading:2453091-...lld:pubmed
pubmed-article:2453091pubmed:meshHeadingpubmed-meshheading:2453091-...lld:pubmed
pubmed-article:2453091pubmed:meshHeadingpubmed-meshheading:2453091-...lld:pubmed
pubmed-article:2453091pubmed:meshHeadingpubmed-meshheading:2453091-...lld:pubmed
pubmed-article:2453091pubmed:meshHeadingpubmed-meshheading:2453091-...lld:pubmed
pubmed-article:2453091pubmed:meshHeadingpubmed-meshheading:2453091-...lld:pubmed
pubmed-article:2453091pubmed:meshHeadingpubmed-meshheading:2453091-...lld:pubmed
pubmed-article:2453091pubmed:year1988lld:pubmed
pubmed-article:2453091pubmed:articleTitleCarboplatin (JM 8), adriamycin and cyclophosphamide (JAC) in advanced ovarian carcinoma: a pilot study.lld:pubmed
pubmed-article:2453091pubmed:affiliationIstituto Nazionale per la Ricerca sul Cancro, Genova.lld:pubmed
pubmed-article:2453091pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2453091pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed